How NodThera’s NLRP3 Marks A New Era for Obesity Treatment episode artwork

EPISODE · Dec 18, 2025 · 41 MIN

How NodThera’s NLRP3 Marks A New Era for Obesity Treatment

from Leading Beyond The Lab

Cardio-metabolic diseases are the world’s biggest killer. But what if the next generation of treatments could change everything?This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, SGLT2, PCSK9 and now the emerging NLRP3 inhibitor class. His work spans companies such as Novo Nordisk, Amgen, Boehringer Ingelheim and his move into biotech with NodThera marks a shift from big-Pharma leadership into next-wave therapeutic development.In this episode, Jyothis covers:- How NodThera is shaping the future of metabolic and inflammatory disease treatment.- A look at the mindset and challenges behind leading in a high-stakes biotech environment.- Why the right investors often play a critical mentorship role in biotech growth.- Exploring why endocrinology remains underfunded and overlooked in biotech circles.- How he previously worked with Eli Lilly (led by David Ricks), contributing to their efforts in the cardiometabolic space.- Reflections on personal legacy, long-term impact, and how to get in touch.If you’re interested in cardio-metabolic innovation, GLP-1 evolution, biotech strategy or leadership at the cutting edge of science, this episode is worth your time.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.comYoutube: https://www.youtube.com/@life_sciencesJyothis GeorgeCMO at NodTheraLinkedIn: https://www.linkedin.com/in/jyothisgeorge/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:01:40 NodThera's Role in Future Endocrinology10:48 Leadership in Biotech21:05 Investment and Mentorship30:58 Endocrinology's Underinvestment38:13 Jyothis George: Legacy & Contact Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Dec 18, 2025

Embed this episode

NOW PLAYING

How NodThera’s NLRP3 Marks A New Era for Obesity Treatment

0:00 41:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Leading Beyond The Lab?

This episode is 41 minutes long.

When was this Leading Beyond The Lab episode published?

This episode was published on December 18, 2025.

Can I download this Leading Beyond The Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!